PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.44%
EBIT growth of 10.44% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
10.44%
Operating income growth of 10.44% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand.
10.28%
Net income growth of 10.28% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
12.12%
EPS growth of 12.12% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
10.49%
Diluted EPS growth of 10.49% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
2.21%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.06%
Negative OCF growth while Healthcare median is -9.75%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-28.93%
Negative FCF growth while Healthcare median is -5.82%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4997.65%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
52.56%
OCF/share CAGR of 52.56% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
56.42%
3Y OCF/share growth of 56.42% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-10058.37%
Negative 10Y net income/share CAGR vs. Healthcare median of 11.07%. Seth Klarman might see a fundamental problem if peers maintain growth.
92.69%
5Y net income/share CAGR > 1.5x Healthcare median of 13.32%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
51.37%
3Y net income/share CAGR > 1.5x Healthcare median of 8.28%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
741.48%
Equity/share CAGR of 741.48% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
108.54%
5Y equity/share CAGR > 1.5x Healthcare median of 7.03%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
-89.94%
Negative 3Y equity/share growth while Healthcare median is 2.61%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.83%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-40.69%
Negative BV/share change while Healthcare median is -0.39%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
499.58%
Debt growth of 499.58% while Healthcare median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
-14.73%
R&D dropping while Healthcare median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
3.54%
SG&A growth of 3.54% while Healthcare median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.